Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0920646 (
renal ischemia
)
2,515
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
PACAP
(pituitary adenylate cyclase-activating polypeptide) occurs in two biologically active forms, with 38 and 37 amino acid residues (PACAP38 and PACAP27). In mammalian tissues, PACAP38 is the dominant form. Diverse effects have been described in the cardiovascular, respiratory, gastrointestinal, and urogenital systems.
PACAP
is known for its strong cytoprotective effects, which are present endogenously as well, as proven by knockout studies and results showing that
PACAP
is up-regulated following diverse injuries. Little is known about such effects in the kidney. We have previously shown that
PACAP
is protective in
renal ischemia
-reperfusion injury. Therefore, the aim of the present study was to investigate the changes of endogenous
PACAP
following 60-minute
renal ischemia
using radioimmunoassay. Changes were observed within 24 hours following renal vessel clamping. In the cortex, an acute decrease was followed by an increase on the intact side, and levels returned to original ones on the operated side. In the medulla, changes were only observed on the clamped side: a marked up-regulation was detected in PACAP38-like immunoreactivity within the first 24 hours. The present study showed that PACAP38- and PACAP27-like immunoreactivities sensitively react to
renal ischemia
-reperfusion, the physiological importance of which awaits further investigation.
...
PMID:Changes in pituitary adenylate cyclase-activating polypeptide following renal ischemia-reperfusion in rats. 2069 63
Pituitary adenylate cyclase activating polypeptide (
PACAP
) is a multifunctional neuropeptide occurring in the nervous system as well as in the peripheral organs. Beneficial action of
PACAP
has been shown in different pathological processes. The strong protective effects of the peptide are probably due to its complex modulatory actions in antiapoptotic, anti-inflammatory and antioxidant pathways. In the kidney,
PACAP
is protective in models of diabetic nephropathy, myeloma kidney injury, cisplatin-, gentamycin- and cyclosporin-induced damages. Numerous studies have been published describing the protective effect of this peptide in
renal ischemia
/reperfusion. The present review focuses on the ischemia/reperfusion-induced kidney injury and gives a brief summary about the results published in this area.
...
PMID:The effects of pituitary adenylate cyclase activating polypeptide in renal ischemia/reperfusion. 2547 76